-
Eli Lilly Completes Acquisition of Point Biopharma, Expanding Radiopharmaceutical Portfolio
•
Eli Lilly (NYSE: LLY) has finalized its acquisition of radiopharmaceutical company Point Biopharma (NASDAQ: PNT) this week, following the clearance of the last regulatory requirement last month. As part of the acquisition, Lilly gains access to Point’s PNT2002, a PSMA-targeting radiopharmaceutical currently in Phase III trials for metastatic castration-resistant prostate…
-
BMS Expands Oncology Portfolio with $4.1 Billion RayzeBio Acquisition
•
Bristol Myers Squibb (BMS; NYSE: BMY) has announced the acquisition of RayzeBio (NASDAQ: RYZB), a clinical-stage developer of actinium-based radiopharmaceutical therapeutics (RPT), bolstering its oncology portfolio. BMS will purchase all outstanding shares of RayzeBio for an estimated $4.1 billion, with the transaction anticipated to close in the first half of…
-
Eli Lilly Clears Final Regulatory Hurdle with NRC Approval for Point Biopharma Acquisition
•
The Nuclear Regulatory Commission (NRC) of the US has given its approval for the transfer of a radioactive materials license from Point Biopharma (NASDAQ: PNT) to Eli Lilly (NYSE: LLY). This decision marks the final regulatory clearance necessary for Eli Lilly’s acquisition of Point Biopharma, which was announced last month.…
-
Eli Lilly Acquires Point Biopharma to Enhance Oncology Portfolio
•
Eli Lilly (NYSE: LLY) announced last week its agreement to acquire radiopharmaceutical company Point Biopharma (NASDAQ: PNT) in a strategic move to bolster its oncology portfolio with several pre-clinical and clinical radioligand candidates. The acquisition, valued at USD 1.4 billion, will involve Lilly purchasing all outstanding shares of Point through…
